Lv5
880 积分 2023-08-07 加入
Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial
1小时前
待确认
Current landscape of targeted therapy in esophageal squamous cell carcinoma
7小时前
已完结
Identification of reversible OATP1B1 and time-dependent CYP3A4 inhibition as the major risk factors for drug-induced cholestasis (DIC)
5个月前
已完结
In Silico and in Vitro Assessment of OATP1B1 Inhibition in Drug Discovery
5个月前
已完结
Proposal of a Parameter for OATP1B1 Inhibition Screening at the Early Drug Discovery Stage
5个月前
已完结
In Silico Enabled Discovery of KAI-11101, a Preclinical DLK Inhibitor for the Treatment of Neurodegenerative Disease and Neuronal Injury
5个月前
已完结
A Critical Assessment of Combined Ligand- and Structure-Based Approaches to hERG Channel Blocker Modeling
5个月前
已完结
Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches
5个月前
已完结
New potential binding determinant for hERG channel inhibitors
5个月前
已完结
Toward a Pharmacophore for Drugs Inducing the Long QT Syndrome: Insights from a CoMFA Study of HERG K+ Channel Blockers
5个月前
已完结
皖公网安备34019202002308
